All studies
RecruitingPHASE3INTERVENTIONAL

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

Rett syndrome is a rare genetic condition that affects how the brain develops, causing severe physical and communication challenges. There are currently very few treatments to manage these daily difficulties. This study is testing a medicine called fenfluramine hydrochloride to see if it can help relieve common symptoms. Participants will take either the study medicine or a dummy medicine known as a placebo. A placebo looks identical but has no active ingredients. Comparing the two helps scientists clearly see whether any changes are truly caused by the study drug. The trial is open to people aged 5 to 35 who have a confirmed diagnosis of typical Rett syndrome and have been in a stable phase of the condition for at least six months. A regular parent or carer must also take part to help track symptoms throughout the study.

At a glance

Status
Recruiting
Phase
PHASE3
Sponsor
UCB BIOSCIENCES, Inc.
Enrolment target
200
Start
14 Jul 2026
Estimated completion
29 Aug 2031

What is this study about?

Rett syndrome is a rare neurological condition that almost always affects girls, though boys can occasionally have it. It is usually caused by a change in a gene called MECP2. After developing normally in early infancy, children with Rett syndrome gradually lose skills they once had, such as speech, purposeful hand movements, and walking. Finding treatments that can ease these symptoms and improve quality of life is an urgent goal for families and doctors.

This Phase 3 study focuses on an oral liquid medicine called fenfluramine hydrochloride. While it is already approved in some countries to help treat certain rare types of epilepsy, researchers want to see if it can also help people with Rett syndrome. They hope the medicine might support brain signaling to improve day-to-day abilities, alertness, and overall well-being.

Because this is a Phase 3 trial, it is one of the final testing stages required before a medicine can be considered for wider prescription. Half of the participants will receive fenfluramine, while the other half will receive a placebo. Neither the families nor the study doctors will know who is getting which treatment until the trial ends. This careful setup ensures the results are completely fair and reliable.

Key takeaways

  • Tests whether fenfluramine can safely ease symptoms of Rett syndrome.
  • Open to people aged 5 to 35 with classic Rett syndrome and a confirmed MECP2 gene change.
  • Participants must have had stable symptoms for at least six months.
  • Half of the participants will receive the active medicine and half will receive a dummy liquid (placebo).
  • Requires a regular parent or adult carer to help report on daily progress.

Who may be eligible?

This trial is open to children and adults aged 5 to 35 who have classic or typical Rett syndrome. Participants must have a confirmed change in the MECP2 gene, which is checked with a genetic test.

To be eligible, the person must be in the 'post-regression' stage. This means their condition has been stable for at least six months, with no recent sudden loss in their ability to walk, use their hands, speak, or communicate with eye contact. They must also have a dedicated adult carer who knows them well and can attend study appointments to answer questions.

People cannot join if they have had certain serious illnesses, such as leukaemia, lymphoma, or other cancers within the past five years (except for successfully treated skin cancers). They also cannot take part if they have unstable vital signs, such as heart rate or blood pressure issues that make taking part unsafe.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Aged between 5 and 35 years old.
  2. Diagnosed with classic Rett syndrome with a confirmed MECP2 gene change.
  3. Skills such as walking, hand use, or eye contact have been stable for at least 6 months.
  4. Has an adult parent or carer available to attend visits and complete questionnaires.
  5. No history of cancer (such as leukaemia or lymphoma) in the last 5 years.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves attending regular visits at a specialist hospital clinic. Before starting, the study team will carry out health checks, such as blood tests, heart checks, and physical exams, to make sure it is safe for your family member to join.

Participants will take a liquid medicine by mouth or feeding tube every day. During clinic visits, doctors will monitor health, check for any side effects, and measure changes in Rett syndrome symptoms. Because people with Rett syndrome often cannot speak for themselves, the main carer will complete regular questionnaires about daily behaviours, sleep, and communication. The trial team will explain the exact number of visits and total duration before you agree to take part.

Potential risks and benefits

Participants might see an improvement in their symptoms, but there is no guarantee the medicine will help. There is also a 50% chance of receiving a placebo, which provides no medical benefit. Like all medicines, fenfluramine can cause unwanted side effects, which the medical team will watch closely. Taking part helps doctors learn more about Rett syndrome and may help others in the future. Joining is completely voluntary, and you can leave the study at any time without it affecting your family's normal NHS care.

Locations (46)

  • Ep0247 21010
    Verified postcode
    Little Rock, United States· Recruiting
  • Ep0247 21009
    Verified postcode
    Miami, United States· Recruiting
  • Ep0247 21011
    Verified postcode
    Orlando, United States· Recruiting
  • Ep0247 21007
    Verified postcode
    Atlanta, United States· Recruiting
  • Ep0247 21003
    Verified postcode
    Philadelphia, United States· Recruiting
  • Ep0247 21005
    Verified postcode
    Houston, United States· Recruiting
  • Ep0247 21013
    Verified postcode
    Irving, United States· Recruiting
  • Ep0247 21004
    Verified postcode
    Seattle, United States· Recruiting
  • Ep0247 11001
    Verified postcode
    Brussels, Belgium· Recruiting
  • Ep0247 11002
    Verified postcode
    Edegem, Belgium· Recruiting
  • Ep0247 42001
    Verified postcode
    Beijing, China· Recruiting
  • Ep0247 42009
    Verified postcode
    Shanghai, China· Recruiting

Common questions

What is a placebo and why is it used?

A placebo is a dummy medicine that looks and tastes identical to the real treatment but contains no active drug. It helps doctors confirm whether any health changes are genuinely caused by the study medicine.

Will we definitely receive the study medicine?

No. Participants are placed into groups by chance, like flipping a coin. You have an equal chance of receiving either the real medicine or the placebo.

Does it cost anything to take part?

No. The study medication, clinic visits, and all trial-related tests are provided free of charge. Travel expenses to the hospital may also be covered.

Can boys with Rett syndrome join this study?

Yes. Although Rett syndrome is far more common in girls, the trial is open to both males and females who meet the health criteria.

What happens if we change our minds?

You are free to leave the trial at any point, for any reason. Deciding to leave will not affect your regular medical care or relationship with your doctor.

How to find out more

UCB Cares

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndro…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.